Effects of Fish Oil on the Colon Mucosa
Phase Ib Study of the Effects of Omega-3 Supplementation on Fatty Acid Metabolism in the Colon
1 other identifier
interventional
48
1 country
1
Brief Summary
The purpose of this study is to see what effects the dietary supplement called Omega-3 or "Fish Oil" and it has on your colon, if any. Omega-3 (Fish Oil) is available in many forms (pills, capsules, liquid) in grocery stores, health food/vitamin stores and drug stores and from eating fish. We would like to learn if different amounts of Fish Oil specifically chosen for you individually change your colon tissue (large intestine). We hope that Fish Oil may be useful in the future as something that may help to prevent colon cancer, but we don't have any research in humans that shows that yet. We have to do this study first to see if Fish Oil effects the colon. One type of Fish Oil is has been approved by the U.S. Food and Drug Administration (FDA) to reduce the risk of heart disease. We are going to test a different Fish Oil supplement made by a company called Nordic Naturals. The colon lining or "mucosa" comes in contact with all the undigested things we eat or drink as it passes out to waste (stool). Animal studies suggest that fish oil may help the colon lining by reducing colon polyps and therefore colon cancer. We think this happens through chemical changes in the colon lining and also in the blood. The chemicals that we are looking at are called "fatty acids". We want to see if taking different amounts fish oil chosen for you changes these chemicals (fatty acids) in your colon or your blood. We will assign you a personal "low dose" of fish oil to take for 2 weeks, followed by a "high dose, or maximum" dose for 2 weeks. We will calculate your basal Metabolic Rate (BMR) from your height, weight, age and assess your activity factor. We have a table that then tells us your target low and high dose. Then, based on your blood samples, we figure out which target dose is the one for you that will change these chemicals (fatty acids) by about ½ (50%). We will check how well this process worked by collecting small pieces of colon tissue (biopsies) of the colon before any fish oil and after all the fish oil is consumed. We will also use blood samples to test for these fatty acids and a few others. We are going to collect diet information at several times throughout the study so we can see if the food you eat makes a difference too. We hope to learn a lot about how fatty acids are metabolized (broken down or used) in the colon directly in combination with Omega-3 supplements.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for phase_1
Started May 2013
Typical duration for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2013
CompletedFirst Submitted
Initial submission to the registry
May 9, 2013
CompletedFirst Posted
Study publicly available on registry
May 22, 2013
CompletedPrimary Completion
Last participant's last visit for primary outcome
February 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2016
CompletedMarch 1, 2017
February 1, 2017
2.8 years
May 9, 2013
February 27, 2017
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Change in PGE2 levels in colon mucosa
Quantitate the amount of PGE2 in colon mucosa before and after 5 months of Fish Oil
5 months
Study Arms (1)
Fish Oil
OTHERInterventions
Eligibility Criteria
You may qualify if:
- Men and women who are between the ages of 25 and 75.
- The subject has been properly informed of the study and signed the informed Consent document(s).
- BMI is between 18 to 40.0 kg/m2
- Pre-menopausal women with intact female reproductive organs must have a negative pregnancy test within 2 weeks of the baseline flexible sigmoidoscopy. Post-menopausal is defined as no menses for the previous 12 months. If cessation of menses is within 12 months then the subject should be treated as pre-menopausal and a pregnancy test performed.
- Have a normal WBC, hemoglobin and platelet count, and renal and hepatic function obtained within the last 28 days
You may not qualify if:
- Pregnant or lactating women or women contemplating pregnancy for the duration of the protocol.
- Taking any of the following chronic medications:
- Insulin or oral hypoglycemics
- Anti-coagulants (or off 3 months prior to study start)
- Lovaza™ (prescription fish oil)
- Chronic NSAID use (including daily 325 mg or more of aspirin) or willing to go off NSAIDS for 3 weeks prior to enrollment to end of study (tDay 84)
- Steroids (except inhaled steroids for asthma)
- Other medications that may affect the biomarkers of interest
- Any supplement use (i.e. High dose vitamins, fish oils, other oils) that can affect the biomarkers of interest. Potential subjects will be given the option of participating if they agree to a 3-week wash-out period before starting on study and to avoid such supplements while on study.
- Has a history of any prior cancer diagnosed within the last 5 years except for basal cell or squamous cell tumors of the skin that have been surgically excised.
- Unable to read, write, or understand English.
- Unable to give informed consent.
- Blood pressure ≥ 150/95 (manual reading).
- Unwilling to avoid intake of non-steroidal anti-inflammatory agents or corticosteroids over a 3 week period prior to study or during the entire study period.
- Showing evidence of lack of reliability or nonadherence (for example, missing a screening or enrollment appointment more than twice)
- +3 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Michigan
Ann Arbor, Michigan, 48109, United States
Related Publications (2)
Sen A, Zhao L, Djuric Z, Turgeon DK, Ruffin MT, Smith WL, Brenner DE, Normolle DP. An Adaptive Bayesian Design for Personalized Dosing in a Cancer Prevention Trial. Am J Prev Med. 2020 Oct;59(4):e167-e173. doi: 10.1016/j.amepre.2020.04.023.
PMID: 32951684DERIVEDDjuric Z, Bassis CM, Plegue MA, Sen A, Turgeon DK, Herman K, Young VB, Brenner DE, Ruffin MT. Increases in Colonic Bacterial Diversity after omega-3 Fatty Acid Supplementation Predict Decreased Colonic Prostaglandin E2 Concentrations in Healthy Adults. J Nutr. 2019 Jul 1;149(7):1170-1179. doi: 10.1093/jn/nxy255.
PMID: 31051496DERIVED
MeSH Terms
Interventions
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- OTHER
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Project Manager
Study Record Dates
First Submitted
May 9, 2013
First Posted
May 22, 2013
Study Start
May 1, 2013
Primary Completion
February 1, 2016
Study Completion
October 1, 2016
Last Updated
March 1, 2017
Record last verified: 2017-02